UBS Maintains Neutral on Kanzhun, Raises Price Target to $23.5
$BZ
Computer Software: Programming Data Processing
Technology
UBS analyst Wei Xiong maintains Kanzhun (NASDAQ:BZ) with a Neutral and raises the price target from $22 to $23.5.
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/21/2025 | $26.00 | Neutral → Buy | UBS |
| 12/9/2024 | $15.00 | Outperform → Mkt Perform | Bernstein |
| 11/18/2024 | $18.00 | Outperform | CLSA |
| 7/25/2024 | Buy → Neutral | Daiwa Securities | |
| 5/24/2024 | $30.00 | Buy | HSBC Securities |
| 3/13/2024 | $17.00 → $25.00 | Neutral → Buy | New Street |
| 3/12/2024 | Neutral → Outperform | Macquarie | |
| 12/20/2023 | $17.00 | Neutral | New Street |
4 - Kanzhun Ltd (0001842827) (Issuer)
4 - Kanzhun Ltd (0001842827) (Issuer)
4 - Kanzhun Ltd (0001842827) (Issuer)
BEIJING, March 27, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED ("BOSS Zhipin" or the "Company") (NASDAQ:BZ, HK: 2076)) today announced the continued execution of its share repurchase program, utilizing around RMB23.6 million to repurchase 506,252 ordinary shares on March 26. Year-to-date in 2026, the Company has deployed over RMB500 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns. CONTACT: PIACENTE·FINANCIAL COMMUNICATIONS [email protected]
BEIJING, March 26, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED ("BOSS Zhipin" or the "Company") (NASDAQ:BZ, HK: 2076)) today announced the continued execution of its share repurchase program, utilizing around RMB34.4 million to repurchase 748,460 ordinary shares on March 25. Year-to-date in 2026, the Company has deployed over RMB480 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns. CONTACT: PIACENTE·FINANCIAL COMMUNICATIONS [email protected]
BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED ("BOSS Zhipin" or the "Company") (NASDAQ:BZ, HK: 2076)) today announced the continued execution of its share repurchase program, utilizing around RMB34.4 million to repurchase 748,552 ordinary shares on March 24. Year-to-date in 2026, the Company has deployed nearly RMB450 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns. On March 18, 2026, the Company's board of directors (the "Board") approved amendments to the existing share repurchase program, increasing the total authorization under the program to repurchase up to US$400 million of the Company's shares (including
6-K - Kanzhun Ltd (0001842827) (Filer)
6-K - Kanzhun Ltd (0001842827) (Filer)
6-K - Kanzhun Ltd (0001842827) (Filer)
UBS upgraded Kanzhun Limited from Neutral to Buy and set a new price target of $26.00
Bernstein downgraded Kanzhun Limited from Outperform to Mkt Perform and set a new price target of $15.00
CLSA initiated coverage of Kanzhun Limited with a rating of Outperform and set a new price target of $18.00
BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED ("BOSS Zhipin" or the "Company") (NASDAQ:BZ, HK: 2076)) today announced the continued execution of its share repurchase program, utilizing around RMB34.4 million to repurchase 748,552 ordinary shares on March 24. Year-to-date in 2026, the Company has deployed nearly RMB450 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns. On March 18, 2026, the Company's board of directors (the "Board") approved amendments to the existing share repurchase program, increasing the total authorization under the program to repurchase up to US$400 million of the Company's shares (including
BEIJING, March 23, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED ("BOSS Zhipin" or the "Company") (NASDAQ:BZ, HK: 2076)) today announced the continued execution of its share repurchase program, utilizing around RMB34.5 million to repurchase 733,918 ordinary shares on March 20. Year-to-date in 2026, the Company has deployed around RMB380 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns. On March 18, 2026, the Company's board of directors (the "Board") approved amendments to the existing share repurchase program, increasing the total authorization under the program to repurchase up to US$400 million of the Company's shares (including
BEIJING, March 18, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (the "Company") today announced that its board of directors (the "Board") has approved an amendment to its existing share repurchase program and a shareholder return target. On March 18, 2026, the Board approved amendments to the existing share repurchase program, increasing the total authorization under the program to repurchase up to US$400 million of the Company's shares (including ADSs) over the extended term of the program through August 28, 2027, as a sign of confidence in the Company's continued growth in the future. In August 2025, the Company approved an annual dividend policy (the "Dividend Policy"), pursuant to which
BEIJING, Aug. 20, 2025 (GLOBE NEWSWIRE) -- KANZHUN LIMITED ("BOSS Zhipin" or the "Company") (NASDAQ:BZ, HKEX: 2076)), a leading online recruitment platform in China, today announced that Ms. Mengyuan Dong has resigned as an independent non-executive director of the Company in order to devote more time to her other personal business commitments, effective on August 20, 2025. In addition, with effect from August 20, 2025, Ms. Hongyu Liu, an independent non-executive director and a member of the nomination committee has been appointed as the chairman of the audit committee and a member of the corporate governance committee. Mr. Yan Li, an independent non-executive director, the chairman of t
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, today announced the successful completion of a $42 million Series A financing. The financing round was led by Lanchi Ventures, a preeminent global early-stage technology investor known for backing breakthrough innovations, with participation from an elite syndicate of new investors including Yuanbio Venture Capital, Legend Capital and C&D Eme
BEIJING, June 17, 2024 (GLOBE NEWSWIRE) -- Kanzhun Limited (NASDAQ:BZ), which operates China's largest online recruitment platform BOSS Zhipin*, visits the Nasdaq MarketSite in Times Square. Founded in 2014, BOSS Zhipin is a pioneer in introducing a next-generation Direct Recruitment Model which is transforming China's online recruitment industry. The mobile-native product promotes instant direct communication between recruiters and job seekers, delivers accurate matching results through its proprietary recommendation algorithms powering by big data insights. Benefiting from the unique business model and strong technology capability, BOSS Zhipin connects job seekers and enterprise users
SC 13G/A - Kanzhun Ltd (0001842827) (Subject)
SC 13G/A - Kanzhun Ltd (0001842827) (Subject)
SC 13G/A - Kanzhun Ltd (0001842827) (Subject)